Pfizer

Latest Articles

Alan Schwartz Makes Guggenheim Partners an M&A Player

Allergan-Pfizer Merger Gives Pharma a Growth Injection

Ben Thorpe Helps Keep Goldman’s Health M&A Franchise in Top Shape

David Rothnie

Daily Agenda: Can U.S. Strength Kick-start Global Growth?

Andrew Barber

Daily Agenda: Commodity Rout Continues

Andrew Barber

Daily Agenda: Liquidity Fuels Continuing M&A Boom

Andrew Barber

Daily Agenda: Mixed Signals Complicate Fed Prediction

Andrew Barber

Daily Agenda: Oil Prices Fall on Robust Supply

Andrew Barber

Health Care Buying Spree

How to Profit from Faster FDA and Better Science

Fran Hawthorne

Pfizer And AstraZeneca's Billion Dollar Battle

In Event-Driven Strategy Hedge Funds, M&A is the Headliner

David Turner

Investing in a Cure for Cancer

Kaitlin Ugolik

Investing in the Health Care Revolution

Kaitlin Ugolik

Jack Levy: Strategic Thinking And People Skills

Xiang Ji

KKR Gets Nod To Acquire Capsugel

KKR To Buy Capsugel For $2.38B

Perella Weinberg’s Andrew Bednar Drives Stock Exchange Megadeals

David Rothnie

Premium

Pfizer-Wyeth: It's a chemical reaction

Contact Info

New York
1270 Avenue of the Americas, Suite 1100
New York, NY 10020
P: +1 212 224 3300

London
4 Bouverie Street
London EC4Y 8AX
P: +44 207 779 8888

Hong Kong
Unit 2488, 24/F
Lee Garden One,
33 Hysan Avenue
Causeway Bay, Hong Kong
P: +852 2912 8001

Corporate

About Us

Leadership Team

Careers

II Press Room

Digital

Masthead

Thought Leadership

Display Advertising

Reprints

FAQs

Events

Events Calendar

Memberships

Subscription

Subscribe to Premium

Register

Register for Free Account

Newsletters

Sign up for II newsletters

© 2025 Institutional Investor LLC. All material subject to strictly enforced copyright laws. Please read our Terms & Conditions, Modern Slavery Act Transparency Statement, Accessibility Statement and Privacy Policy before using the site.

develop build:2025-12-17 Login